Recently US corporation Turing Pharmaceuticals bought the rights to daraprim, a drug used to treat toxoplasmosis, and promptly announced it was increasing the cost from (US)$13.50 per tablet to $750. The same drug is sold in the UK for around $20 for 30 tablets.
When this news became public knowledge there was outrage. Social media went into overdrive, causing Turing to capitulate and announce that it will be reviewing the pricing of daraprim. By how much remains to be seen.
Turing’s CEO saw the rights to the medication as a market opportunity. He felt the market was prepared to pay a lot more for this drug and there was money to be made. And the role of any good CEO is to make as much money as possible for their company. Or more precisely, the company directors and shareholders. Continue reading